What is HC Wainwright’s Estimate for Kamada FY2025 Earnings?

Kamada Ltd. (NASDAQ:KMDA) – HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Kamada in a research report issued to clients and investors on Thursday, March 6th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn $0.28 per share for the year, down from their prior forecast of $0.31. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada’s FY2026 earnings at $0.38 EPS, FY2027 earnings at $0.45 EPS and FY2028 earnings at $0.54 EPS.

Kamada Stock Up 0.6 %

NASDAQ:KMDA opened at $7.12 on Monday. Kamada has a twelve month low of $4.74 and a twelve month high of $9.15. The business has a 50 day moving average price of $7.18 and a two-hundred day moving average price of $6.19. The company has a market cap of $409.26 million, a P/E ratio of 25.43, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97.

Hedge Funds Weigh In On Kamada

A number of large investors have recently bought and sold shares of the company. Plato Investment Management Ltd bought a new stake in shares of Kamada during the 3rd quarter worth approximately $117,000. Public Employees Retirement System of Ohio bought a new stake in shares of Kamada during the 3rd quarter worth approximately $77,000. JPMorgan Chase & Co. bought a new stake in shares of Kamada during the 4th quarter worth approximately $67,000. NewEdge Advisors LLC raised its stake in shares of Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 8,260 shares in the last quarter. Finally, Aristides Capital LLC raised its stake in shares of Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 6,850 shares in the last quarter. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Dividend Announcement

The company also recently declared a dividend, which will be paid on Monday, April 7th. Shareholders of record on Monday, March 17th will be given a dividend of $0.20 per share. The ex-dividend date is Monday, March 17th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.